

THORATEC CORP
Form 10-Q/A
January 24, 2002

Table of Contents

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**Amendment
No. 1 to**

FORM 10-Q

(Mark one)

Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the quarterly period ended June 30, 2001 or

Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the transition period from _____ to _____

COMMISSION FILE NUMBER: 1-8145

THORATEC CORPORATION

(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction of incorporation or organization)

94-2340464
(I.R.S. Employer Identification No.)

6035 Stoneridge Drive, Pleasanton, California
(Address of principal executive offices)

94588
(Zip Code)

Registrant's telephone number, including area code: (925) 847-8600

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

As of August 10, 2001, registrant had 55,140,400 shares of common stock outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED BALANCE SHEETS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE OF MARKET RISK

PART II. OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

SIGNATURES

Table of Contents

THORATEC CORPORATION AND SUBSIDIARIES

INDEX

PART I. FINANCIAL INFORMATION

3

ITEM 1. Condensed
Consolidated Financial
Statements

3

Condensed
Consolidated Balance
Sheets as of June 2001
and Year End 2000

3

Condensed
Consolidated
Statements of
Operations for the Three
and Six Months Ended
June 2001 and June
2000

5

Condensed
Consolidated
Statements of Cash
Flows for the Six
Months Ended June
2001 and June 2000

6

Condensed
Consolidated
Statements of
Comprehensive Income
(Loss) for the Three and
Six Months Ended June
2001 and June 2000

7

Notes to Condensed
Consolidated Financial
Statements

8

ITEM 2. Management's
Discussion and Analysis
of Financial Condition
and Results of
Operations

14

ITEM 3. Quantitative
and Qualitative
Disclosure of Market
Risk

17

PART II. OTHER
INFORMATION

19

ITEM 2. Changes in
Securities

Edgar Filing: THORATEC CORP - Form 10-Q/A

19

ITEM 4. Submission of
Matters to a Vote of
Security Holders

19

ITEM 6. Exhibits and
Reports on Form 8-K

19

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(in thousands, except common shares data)****(Unaudited)**

	<u>June</u>	<u>December</u>
	2001	2000
ASSETS		
Current assets:		
Cash and cash equivalents	\$3,513	\$30,236
Short-term available-for-sale investments at quoted market value (amortized cost of \$77,725 in 2001 and \$98,743 in 2000)	77,725	98,682
Receivables (net of allowances of \$1,262 in 2001 and \$939 in 2000)	20,074	15,358
Inventories	27,643	17,381
Deferred tax asset	10,365	3,454
Prepaid expenses and other	1,055	74
<hr/>		
<hr/>		
Total current assets	140,375	165,185
Equipment and improvements, net	18,957	7,084
Restricted cash	45,723	
Goodwill	98,124	
Purchased intangible assets	204,873	
Other assets	4,943	4,416

TOTAL ASSETS
\$512,995 \$176,685

See notes to condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(in thousands, except common shares data)
(Unaudited)

	<u>June 2001</u>	<u>December 2000</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable		
\$6,092	\$3,972	
Accrued compensation		
5,124	4,976	
Accrued merger and restructuring		
2,900	1,708	
Estimated liabilities for warranty, legal and other		
1,954	1,316	
Other accrued liabilities		
4,730	4,006	
<hr/>		
Total current liabilities		
20,800	15,978	
Subordinated convertible debentures (includes \$1,500 due to Thermo Electron in 2001 and 2000)		
54,838	54,838	
Long-term deferred tax liability and other		
77,993		
<hr/>		
Total liabilities		
153,631	70,816	
Shareholders' equity:		
Common shares, 100,000,000 authorized; issued and outstanding 54,609,734 in 2001 and 33,937,643 in 2000		
388,352	4,064	

Edgar Filing: THORATEC CORP - Form 10-Q/A

Treasury stock at cost, 1,723,150
shares in 2000
(51,869)
Capital in excess of par value
96,930
Deferred compensation
(688) (251)
Retained earnings (accumulated
deficit)
(28,258) 57,025
Accumulated other
comprehensive income (loss):

Unrealized loss on investments
(39)
Cumulative translation
adjustments
(42) 9

Total accumulated other
comprehensive loss
(42) (30)

Total shareholders' equity
359,364 105,869

TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY
\$512,995 \$176,685

See notes to condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 2001	June 2000	June 2001	June 2000
Product sales	\$28,218	\$22,609	\$49,697	\$42,538
Cost of product sales				
12,645 9,400 22,684 17,560				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
Gross margin				
15,573 13,209 27,013 24,978				
<hr/>				
<hr/>				
<hr/>				
<hr/>				
Operating expenses:				
Research and development				
6,430 3,808 11,660 7,914				
Selling, general and administrative				
8,311 6,137 15,642 11,992				
Amortization of goodwill and purchased intangible assets				
4,526 6,807				
In-process research and development				
76,858				
Merger and restructuring costs				
1,605 566 5,145 707				
<hr/>				
<hr/>				

Total operating expenses
20,872 10,511 116,112 20,613

Income (loss) from operations
(5,299) 2,698 (89,099) 4,365
Interest and other income net
591 1,283 1,735 2,494

Income (loss) before taxes and extraordinary item
(4,708) 3,981 (87,364) 6,859
Income tax expense (benefit)
(1,605) 1,533 (2,080) 2,641

Income (loss) before extraordinary item
(3,103) 2,448 (85,284) 4,218
Extraordinary item (Note 11)
191 191

Net income (loss)
\$(3,103) \$2,639 \$(85,284) \$4,409

Earnings (loss) per share:

Basic
\$(0.06) \$0.08 \$(1.73) \$0.14

Diluted
\$(0.06) \$0.08 \$(1.73) \$0.14

Shares used to compute earnings (loss) per share:

Basic
54,629 32,203 49,204 32,183

Diluted
54,629 32,212 49,204 32,213

See notes to condensed consolidated financial statements.

Table of Contents**THORATEC CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(in thousands)****(Unaudited)**

	Six Months Ended	
	June 2001	June 2000
Cash flows from operating activities:		
Net income (loss)		
\$(85,284) \$4,409		
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization		
8,728 1,443		
Write-off of in-process research and development costs		
76,858		
Amortization of deferred compensation		
404 104		
Provision for losses on accounts receivable		
323		
Change in net deferred tax liability		
(2,481)		
Extraordinary item, net of income taxes (Note 11)		
(191)		
Other noncash items		
93		
Changes in assets and liabilities:		
Receivables		
823 (873)		
Inventories		
(2,928) (275)		
Prepaid expenses and other assets		
(246) 47		
Accounts payable and other liabilities		
(5,898) (322)		
Net cash provided by (used in) operating activities		
(9,608) 4,342		

Cash flows from investing activities:

Advances to affiliate, net
(9,130)
Purchases of short-term
available-for-sale investments
(112,069) (28,295)
Maturities of short-term
available-for-sale investments
87,192 36,663
Sales of short-term
available-for-sale investments
58,617
Capitalized transaction costs
(5,838)
Expenditures for equipment and
improvements
(1,459) (1,232)
Cash acquired in business
acquisition
3,456
Reclassification to restricted cash
(45,723)

Net cash used in investing activities
(15,824) (1,994)

Cash flows from financing activities:

Net proceeds from issuance of
common stock
582
Common stock issued upon exercise
of options
415
Payment of withholding taxes
related to employee stock plans
(47)
Repurchase of common stock (Note
12)
(1,733)

Edgar Filing: THORATEC CORP - Form 10-Q/A

Purchase of convertible debentures
(Note 11)
(2,825)

Net cash used in financing activities
(1,318) (2,290)
Effect of exchange rate changes on
cash
27 (41)

Net increase (decrease) in cash and
cash equivalents
(26,723) 17
Cash and cash equivalents at
beginning of period
30,236 418

Cash and cash equivalents at end of
period
\$3,513 \$435

Supplemental Cash Flow
Disclosure:

Cash paid for taxes
\$452 \$2,861
Cash paid for interest
\$1,302 \$1,389

See notes to condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)
(Unaudited)

	Three Months Ended		Six Months Ended	
	June 2001	June 2000	June 2001	June 2000
Net income (loss)	\$ (3,103)	\$ 2,639	\$ (85,284)	\$ 4,409
Other net comprehensive income (loss):				
Unrealized gain (loss) on securities				
(31) 39 (77)				
Foreign currency translation adjustments				
(1) (5) (50) (34)				

Comprehensive income (loss)				
\$(3,104) \$2,603 \$(85,295) \$4,298				

See notes to condensed consolidated financial statements.

Table of Contents

THORATEC CORPORATION AND SUBSIDIARIES

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)**

1. BASIS OF PRESENTATION

The merger of Thoratec Corporation (Thoratec or the Company) with Thermo Cardiosystems Inc. (which subsequently changed its name to Thoratec Cardiosystems Inc. and referred to in this report as Cardiosystems) was completed on February 14, 2001. The interim condensed consolidated financial statements presented have been prepared in accordance with accounting principles generally accepted in the United States of America without audit and, in our opinion, reflect all adjustments necessary (consisting only of normal recurring adjustments) to present fairly the financial position at June 30, 2001 and July 1, 2000, the results of operations for the three and six-month periods ended June 30, 2001 (second quarter and first half 2001) and July 1, 2000 (second quarter and first half 2000) and cash flows for the six-month periods ended June 30, 2001 and July 1, 2000. The merger of Thoratec with Cardiosystems was accounted for as a reverse acquisition because former shareholders of Cardiosystems owned a majority of the outstanding stock of Thoratec subsequent to the merger. For accounting purposes, Cardiosystems is deemed to have acquired Thoratec. Effective July 2, 2001, Thoratec Cardiosystems Inc. and its wholly-owned subsidiary, Nimbus, Inc., were merged into Thoratec Corporation and no longer exist as separate legal entities.

All 2000 financial information presented herein represents the financial position and results of operations and cash flows of Cardiosystems. The 2001 consolidated financial information presented herein includes the financial results of Cardiosystems for the full three and six-month periods ended June 30, 2001 and the financial results of Thoratec for the full three-month period ended June 30, 2001 and for the six-month post-merger period from February 14, 2001 through June 30, 2001. The operating results for any interim period are not necessarily indicative of the results that may be expected for any future period.

The Condensed Consolidated Financial Statements included here have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The accompanying financial statements should be read in conjunction with the fiscal 2000 consolidated financial statements of Thoratec filed with the SEC in our Annual Report on Form 10-K on March 29, 2001 and the fiscal 2000 consolidated financial statements of Cardiosystems filed with the SEC on Form 8-K/A on March 30, 2001.

The preparation of our condensed consolidated financial statements included herein necessarily requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the consolidated balance sheet dates and the reported amounts of revenues and expenses for the periods presented.

We have made certain reclassifications to the 2000 amounts to conform to the 2001 presentation.

2. MERGER OF THORATEC AND CARDIOSYSTEMS

On February 14, 2001, Thoratec completed its merger with Cardiosystems. Pursuant to the merger agreement between Thoratec and Cardiosystems dated October 3, 2000, Thoratec issued 32,226,074 new shares of its common stock to the shareholders of Cardiosystems in exchange for all the outstanding common stock of Cardiosystems (38,594,281 shares outstanding as of February 14, 2001) at an exchange ratio of 0.835 to 1. Immediately following the transaction, Cardiosystems' shareholders owned 59% of the then outstanding common stock of Thoratec and the former Thoratec shareholders owned the remaining shares of Thoratec common stock. Thermo Electron Corporation, the majority shareholder of Cardiosystems prior to the merger, received 19,312,959 shares of the 32,226,074 newly issued shares. Immediately following the merger, Thermo Electron owned 35% of the then outstanding common stock of Thoratec. Pursuant to the terms of a Registration Rights Agreement between the Company and Thermo Electron dated October 3, 2000, the Company filed a Registration Statement on Form S-3 with the SEC on June 15, 2001 to register for resale 4,828,240 shares of the Company's common stock held by Thermo Electron. According to Thermo Electron's filings made with the SEC, Thermo Electron owned 18,312,959 shares of Thoratec as of June 30, 2001 and 15,892,959 shares as of July 5, 2001, representing approximately 34% of the total outstanding shares of Thoratec as of June 30, 2001 and 29% of the outstanding shares as of July 5, 2001.

The merger was accounted for under the purchase method of accounting and was treated as a reverse acquisition because the shareholders of Cardiosystems owned the majority of Thoratec common stock after the merger. Cardiosystems was considered the acquiror for accounting and financial reporting purposes. Due to the reverse acquisition, Thoratec's assets and liabilities were recorded based upon their estimated fair values at the date of acquisition. The operating results of Thoratec have been included in the accompanying condensed consolidated financial

Edgar Filing: THORATEC CORP - Form 10-Q/A

statements from the date of acquisition. As of June 30, 2001, approximately \$309.5 million of the total purchase price of \$346.2 million has been allocated to goodwill and other purchased intangible assets. As a result of the merger, \$76.9 million relating to in-process research and development has been expensed in the first half of 2001. Until the Company adopts

Table of Contents

Statement of Financial Accounting Standard (SFAS) No. 142, Business Combinations, further described in Note 5, goodwill and other intangibles will be amortized over estimated useful lives of six to twenty years beginning February 14, 2001. The Company has recorded a liability for the estimated costs associated with evaluating and restructuring its product distribution networks. Due to uncertainty associated with negotiations related to the cancellation of contracts with third parties, an adjustment to the estimated liability recorded in purchase accounting is possible.

The purchase price and allocation of purchase price as of June 30, 2001 are summarized as follows:

Purchase price:

Common stock
\$306,889
Stock options
33,524
Transaction costs
5,780

Total purchase price
\$346,193

Allocation of purchase price:

Tangible assets acquired
(primarily cash and short-term investments, receivables, inventory, and equipment and improvements)

\$41,018
Fair market valuation of property lease
2,285
Deferred tax asset
4,332
Deferred compensation
841

Intangible net assets acquired:

Patents, trademarks and tradenames, purchased technology and assembled workforce
209,572
Goodwill
99,940
In-process research and development
76,858
Liabilities assumed

(11,260)
 Deferred tax liability
 (77,393)

Total
 \$346,193

The unaudited consolidated results of operations on a pro forma basis as if the merger had occurred as of the beginning of the periods presented are as follows:

	Three Months Ended		Six Months Ended	
	June 2001	June 2000	June 2001	June 2000
Revenue	\$28,218	\$29,869	\$53,222	\$57,404
Net loss *	\$(3,103)	\$(1,533)	\$(89,253)	\$(80,536)
Net loss per share basic and diluted	\$(0.06)	\$(0.03)	\$(1.63)	\$(1.51)

* The three and six-month periods ended June 2001 include \$1.6 and \$6.5 million, respectively, of merger and restructuring costs and the three and six-month periods ended June 2000 include \$566,000 and \$707,000, respectively, of merger and restructuring costs. Each of the three-month periods ended June 2001 and June 2000 includes \$4.5 million of amortization of goodwill and purchased intangibles. Each of the six-month periods ended June 2001 and June 2000 includes a \$76.9 million write-off of in-process research and development costs and \$9.1 million of amortization of goodwill and purchased intangibles.

The pro forma financial information is presented for informational purposes only and is not indicative of the operating results that would have occurred had the merger been consummated as of the above dates, nor are they necessarily indicative of future operating results.

3. MERGER AND RESTRUCTURING EXPENSES

Merger costs of \$768,000 and \$4.3 million, respectively, in the second quarter and first half of 2001 were principally related to employee severance and pre-merger retention costs and outside consulting, accounting, and legal expenses related to the merger between Thoratec and Cardiosystems.

Table of Contents

In June 2001, the Company approved a restructuring plan (the Plan) to consolidate all of its VAD manufacturing operations to its manufacturing facilities and headquarters in Pleasanton, California. The restructuring initiatives, which have already commenced, are related to the Company's desire to provide maximum value to customers through achievement of operating efficiencies. The Company estimates annual savings of at least \$2 million will result upon completion of the Plan. The Plan specifically provides for the reduction of approximately 90 of its manufacturing and related workforce at its Woburn and Chelmsford, Massachusetts facilities, both of which were acquired in the merger with Thermo Cardiosystems in February 2001. Employees affected were notified during the quarter both through direct personal contact and written notification. The Company's HeartMate® family of products, which are currently manufactured at the two Massachusetts facilities, will be transitioned to the Pleasanton facility. The Plan is estimated to take 18 months because of FDA certification requirements for the new manufacturing activities in Pleasanton. During the three months ended June 30, 2001, the Company accrued \$837,000 of restructuring charges during the period, in accordance with Emerging Issues Task Force (EITF) 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity, and Staff Accounting Bulletin (SAB) 100, Restructuring and Impairment Charges. These charges represent estimated severance costs and stock option acceleration charges.

4. EARNINGS (LOSS) PER SHARE

Although Thoratec is the surviving legal entity after the merger, the merger is treated as an acquisition of Thoratec by Cardiosystems for accounting and financial reporting purposes. The weighted average number of common shares previously reported by Cardiosystems has been adjusted for all periods to reflect the exchange ratio of 0.835.

Basic earnings per share for 2001 are computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Options to purchase 6,283,714 shares of common stock for the second quarter of 2001 and for the first six months of 2001 were not included in the computations of diluted earnings per share because the loss positions in both periods would have rendered the additional shares antidilutive. Options to purchase 804,940 shares of common stock for the second quarter of 2000 and 541,915 shares of common stock for the first six months of 2000 were not included in the computations of diluted earnings per share because their effect would have been antidilutive due to the options' exercise prices exceeding the average market price for the common stock. In addition, the computation of diluted earnings per share for each period presented excluded the effect of assuming the conversion of our 4-3/4% subordinated convertible debentures, convertible at \$37.623 per share, because their effect would have been antidilutive. The principal amount of the debentures was \$54.8 million as of the second quarter of 2001 and 2000, respectively.

During the second quarter of 2000, the Company recorded an extraordinary gain of \$191,000 in connection with the repurchase of its 4-3/4% subordinated convertible debentures, which increased basic and diluted earnings per share by \$.01 per share in the first half of 2000. The extraordinary gain had no effect on earnings per share in the second quarter of 2000.

Basic and diluted earnings (loss) per share were calculated as follows:

	Three Months Ended		Six Months Ended	
	June 2001	June 2000	June 2001	June 2000
Net income (loss)	\$ (3,103)	\$ 2,639	\$ (85,284)	\$ 4,409
Weighted average number of common shares-basic	54,629	32,203	49,204	32,183
Dilutive effect of employee stock options				
9 30				

Weighted average number of common shares-diluted

54,629 32,212 49,204 32,213

Net earnings (loss) per common share-basic

\$(0.06) \$0.08 \$(1.73) \$0.14

Net earnings (loss) per common share-diluted

\$(0.06) \$0.08 \$(1.73) \$0.14

Table of Contents**5. RECENTLY ISSUED ACCOUNTING STANDARDS**

In June 2001, the Financial Accounting Standards Board approved SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 141 prospectively prohibits the pooling of interest method of accounting for business combinations initiated after June 30, 2001. SFAS No. 142 requires companies to cease amortizing goodwill that existed at June 30, 2001. The Company's amortization of existing goodwill will cease on December 31, 2001. Any goodwill resulting from acquisitions completed after June 30, 2001 will not be amortized. SFAS No. 142 also establishes a new method of testing goodwill for impairment on an annual basis or on an interim basis if an event occurs or circumstances change that would reduce the fair value of a reporting unit below its carrying value. The adoption of SFAS No. 142 will result in the Company's discontinuation of amortization of its goodwill on December 30, 2001 and the requirement to test its goodwill for impairment under the new standard beginning in the first quarter of fiscal year 2002, which could have an adverse effect on the Company's future results of operations if an impairment occurs.

6. INVENTORIES

Inventories consist of the following:

	<u>June 2001</u>	<u>December 2000</u>
Finished goods	\$8,207	\$3,177
Work in process		
5,138		10,261
Raw materials		
14,298		3,943
<hr/>		
<hr/>		
Total		
\$27,643		\$17,381
<hr/>		
<hr/>		

7. EQUIPMENT AND IMPROVEMENTS

Equipment and improvements consists of property, plant and equipment and rental and support equipment. Rental and support equipment is comprised of drivers and consoles that are rented or loaned to our customers, and periodically may be sold to them. Gross sales proceeds of rental and support equipment are included in product sales with the net book value of the equipment at the date of sale removed from equipment and improvements and included in cost of product sales. Drivers and consoles are manufactured by us and are used to operate our ventricular assist heart pumps. This equipment is capitalized at its historical cost to manufacture and is amortized over its estimated useful life of two to three years.

Equipment and improvements consist of the following:

	<u>June 2001</u>	<u>December 2000</u>
Property, plant and equipment at cost	\$33,594	\$22,005

Edgar Filing: THORATEC CORP - Form 10-Q/A

Less accumulated depreciation
(16,755) (15,324)

Property, plant and equipment, net
16,839 6,681

Rental and support equipment at
cost
4,931 1,763
Less accumulated depreciation
(2,813) (1,360)

Rental and support equipment, net
2,118 403

Total equipment and
improvements, net
\$18,957 \$7,084

8. BUSINESS SEGMENTS AND GEOGRAPHIC DATA

The Company organizes and manages its business by functional operating entity. The Company's functional entities operate in two segments: (1) ventricular assist products and grafts and (2) other medical equipment. The Company's ventricular assist products and

Table of Contents

grafts segment develops, manufactures, and markets proprietary medical devices used for circulatory support and vascular graft applications. The Company's other medical equipment segment develops, manufactures and markets near-patient, whole-blood coagulation and testing equipment and related disposables, as well as premium-quality, single-use, skin-incision devices. The three and six-month periods ended June 2000 include Cardiosystems' ventricular assist products segment and other medical equipment segment. The three and six-month periods ended June 2001 include Cardiosystems' ventricular assist products segment and other medical equipment segment for the full three and six-month periods and Thoratec's ventricular assist products and graft segment for the full three-month period ended June 30, 2001 and for the six-month post-merger period from February 14, 2001 through June 30, 2001.

Business Segments:

Three Months Ended		Six Months Ended	
June 2001	June 2000	June 2001	June 2000

Product sales:

Ventricular assist products and grafts	\$18,038	\$12,615	\$29,225	\$22,788
Other medical equipment	10,180	9,994	20,472	19,750

Total product sales	\$28,218	\$22,609	\$49,697	\$42,538
---------------------	----------	----------	----------	----------

Income (loss) before provision for income taxes:

Ventricular assist products and grafts	\$(745)	\$1,692	\$(3,073)	\$1,731
Other medical equipment	2,231	1,867	4,131	3,876
Corporate (a)	(654)	(295)	(1,347)	(535)
Purchase accounting entries	(4,526)	(83,665)		
Merger and restructuring costs				

Edgar Filing: THORATEC CORP - Form 10-Q/A

(1,605) (566) (5,145) (707)

Total operating income (loss)
 (5,299) 2,698 (89,099) 4,365
 Interest and other income, net
 591 1,283 1,735 2,494

Total income (loss) before taxes and
 extraordinary gain
 \$(4,708) \$3,981 \$(87,364) \$6,859

(a) Represents primarily general and administrative expenses not specifically identified to any particular business segment.
 Geographic Areas:

	Three Months Ended		Six Months Ended	
	June 2001	June 2000	June 2001	June 2000
Product sales:				
Domestic	\$21,590	\$18,924	\$38,533	\$35,890

Europe
3,231 2,039 6,217 4,154
All other international
3,397 1,646 4,947 2,494

Total international
6,628 3,685 11,164 6,648

Total
\$28,218 \$22,609 \$49,697 \$42,538

9. RESTRICTED CASH AND CONVERTIBLE DEBENTURES

In May 1997, the Company issued \$70.0 million worth of 4 3/4% Convertible Subordinated Debentures due May 2004. These debentures were originally issued by Cardiosystems, which was merged into Thoratec and dissolved effective July 2, 2001. The

Table of Contents

current outstanding balance of \$54.8 million reflects repurchases in the open market that have occurred from time to time. Interest is payable semi-annually in November and May of each year. The outstanding debentures are convertible into Company stock at a price of \$37.623 per share. To date, no debentures have been exchanged for shares.

Upon closing of the merger with Cardiosystems in February 2001, \$45.0 million was reclassified to long-term assets from cash and short-term investments to reflect the pledge of collateral as support for a letter of credit guarantee to Thermo Electron Corporation related to Thermo Electron's guarantee of the Company's outstanding subordinated debentures which are due in 2004. The balance of this investment as of June 30, 2001, \$45.7 million, includes interest accumulations.

10. INCOME TAXES

The Company's effective tax benefit rate was 34.1% and 2.4%, respectively, in the second quarter of 2001 and first half of 2001 as compared to an effective tax provision rate of 38.5% in the second quarter of 2000 and first half of 2000. The effective tax benefit rate for 2001 differed from the statutory federal income tax rate primarily due to the nondeductible nature of expenses related to the Company's merger with Cardiosystems, including the write-off of in-process research and development costs, the amortization of goodwill and other nondeductible merger transaction expenses. For 2000, the effective tax provision rate exceeded the federal statutory income tax rate primarily due to the impact of state income taxes.

At June 30, 2001, the Company reported a net deferred tax liability of approximately \$64 million, comprised principally of temporary differences between financial statement and income tax bases of intangible assets. At December 30, 2000, the Company reported a net deferred tax asset of approximately \$6 million, comprised principally of temporary differences between financial statement and income tax bases resulting from differences in the timing of financial statement expense and income tax deductions.

11. EXTRAORDINARY ITEM

During the second quarter of 2000, the Company purchased \$3,173,000 principal amount of its 4-3/4% subordinated convertible debentures for \$2,825,000 in cash, resulting in an extraordinary gain of \$191,000, net of taxes of \$117,000.

12. REPURCHASE OF COMMON STOCK

On April 12, 2001 the Company announced that its board of directors authorized a stock repurchase program under which the Company's common stock with a market value up to \$20 million may be acquired in the open market or in privately negotiated transactions. The number of shares to be purchased and the timing of purchases will be based on several conditions, including the price of Thoratec stock, general market conditions and other factors. During the second quarter of 2001, the Company paid approximately \$1.7 million to repurchase 192,700 shares of its common stock, which were retired.

Table of Contents**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS****Overview**

We develop, manufacture and market proprietary medical devices used for circulatory support, vascular graft, blood coagulation and skin incision applications. We currently market the Thoratec® Ventricular Assist System (Thoratec VAD System or the VAD System) and the HeartMate® Left Ventricular Assist System (HeartMate LVAS) in the United States and internationally for use as a bridge to heart transplantation. Additionally the Thoratec VAD System is marketed for use in the recovery of the heart after open-heart surgery. We have also developed small diameter vascular grafts for use in hemodialysis access and coronary artery bypass surgery. The components of the VAD System and graft products that come into contact with human tissue or blood incorporate Thoralon®, our proprietary biomaterial. Thoralon is a unique biomaterial that provides strength and flexibility to our products with surface properties designed to minimize patient blood clotting and inflammatory response. The HeartMate products incorporate an exclusive textured surface intended to reduce the incidence of thromboembolic complications and the need for systemic anticoagulation.

International Technidyne Corporation (ITC), a wholly-owned subsidiary of Thoratec after the merger with Cardiosystems on February 14, 2001, is a leading manufacturer of near-patient, whole-blood coagulation testing equipment and related disposables, and also manufactures premium-quality, single-use, skin incision devices. ITC operates in a business segment that we call Other Medical Equipment.

Acquisition Event

On February 14, 2001, Thoratec completed its merger with Cardiosystems. Pursuant to the merger agreement between Thoratec and Cardiosystems dated October 3, 2000, Thoratec issued 32,226,074 newly issued shares of its common stock to the shareholders of Cardiosystems in exchange for all the outstanding common stock of Cardiosystems (38,594,281 shares outstanding as of February 14, 2001) at an exchange ratio of 0.835 to 1. Immediately following the transaction, Cardiosystems' shareholders owned 59% of the then outstanding common stock of Thoratec and the former Thoratec shareholders owned the remaining shares of Thoratec common stock. Thermo Electron Corporation, the majority shareholder of Cardiosystems prior to the merger, received 19,312,959 shares of the 32,226,074 newly issued shares. Immediately following the merger, Thermo Electron owned 35% of the then outstanding common stock of Thoratec. Pursuant to the terms of a Registration Rights Agreement between the Company and Thermo Electron dated October 3, 2000, the Company filed a Registration Statement on Form S-3 with the SEC on June 15, 2001 to register for resale 4,828,240 shares of the Company's common stock held by Thermo Electron. According to Thermo Electron's filings made with the SEC, Thermo Electron owned 18,312,959 shares of Thoratec as of June 30, 2001 and 15,892,959 shares as of July 5, 2001, representing approximately 34% of the total outstanding shares of Thoratec as of June 30, 2001 and 29% of the outstanding shares as of July 5, 2001.

The merger was accounted for under the purchase method of accounting and was treated as a reverse acquisition because the shareholders of Cardiosystems owned the majority of Thoratec common stock after the merger. Cardiosystems was considered the acquirer for accounting and financial reporting purposes. Due to the reverse acquisition, Thoratec's assets and liabilities were recorded based upon their estimated fair values at the date of acquisition. The operating results of Thoratec have been included in the accompanying condensed consolidated financial statements from the date of acquisition. As of June 30, 2001, approximately \$309.5 million of the purchase price of \$346.2 million has been allocated to goodwill and other purchased intangible assets. As a result of the merger, \$76.9 million relating to in-process research and development has been expensed in the first half of 2001. Until the Company adopts Statement of Financial Accounting Standard (SFAS) No. 142, Business Combinations, further described in Note 5 to the Condensed Consolidated Financial Statements, the goodwill and other intangibles will be amortized over estimated useful lives of six to twenty years.

Restructuring Plan

In June 2001, the Company approved a restructuring plan (the Plan) to consolidate all of its VAD manufacturing operations to its manufacturing facilities and headquarters in Pleasanton, California. The restructuring initiatives, which have already commenced, are related to the Company's desire to provide maximum value to customers through achievement of operating efficiencies. The Company estimates annual savings of at least \$2 million will result upon completion of the Plan. The Plan specifically provides for the reduction of approximately 90 of its manufacturing and related workforce at its Woburn and Chelmsford, Massachusetts facilities, both of which were acquired in the merger with Thermo Cardiosystems in February 2001. Employees affected were notified during the quarter both through direct personal contact and written notification. The Company's HeartMate® family of products, which are currently manufactured at the two Massachusetts facilities, will be transitioned to the Pleasanton facility. The Plan is estimated to take 18 months because of FDA certification requirements for the new manufacturing activities in Pleasanton. During the three months ended June 30, 2001, the Company accrued \$837,000 of restructuring charges during the period, in accordance with Emerging Issues Task Force (EITF) 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity, and Staff Accounting Bulletin (SAB) 100, Restructuring and Impairment Charges. These charges represent estimated severance costs and stock option acceleration charges.

Table of Contents

Liquidity and Capital Resources

At the end of June 2001, we had working capital of \$119.6 million compared with \$149.2 million at the end of December 2000. Cash, cash equivalents and short-term investments available-for-sale decreased \$47.7 million to \$81.2 million principally due to \$45.0 million in cash and short-term investments being reclassified to restricted cash to reflect the pledge of collateral as support for a letter of credit guarantee to Thermo Electron related to Thermo Electron's guarantee of the Company's outstanding subordinated debentures which are due in 2004. Additionally, the decrease is due to the payment of merger and restructuring costs and for stock repurchases, offset by the addition of Thoratec's cash at the date of the merger and interest earned on corporate cash investments.

The 2001 Statement of Cash Flows was prepared by combining Cardiosystems' balance sheet as of December 2000 with Thoratec's balance sheet as of the merger date of February 14, 2001, and comparing it to the consolidated balance sheet as of June 2001, which included both entities. During the first six months of 2001, \$9.6 million of cash was used in operations. A net decrease in accounts receivable provided \$823,000, primarily from lower sales in the first half of 2001 compared to the fourth quarter of 2000. Uses of cash included \$2.9 million for increased inventory levels following lower than expected sales in the first half of 2001 and anticipated higher sales in future periods and \$5.9 million related to decreased accounts payable and other current liabilities. The decrease in accounts payable and other current liabilities is due largely to payments related to employee severance and pre-merger retention and other merger-related costs.

During the first half of 2001, \$15.8 million of cash was used in investing activities of our Company. Cash in the amount of \$33.7 million was provided from net maturities, sales and purchases of available-for-sale investments and \$3.5 million from Thoratec's beginning cash balance as of the date of the merger. Uses of cash included \$45.7 million to collateralize a letter of credit guarantee to Thermo Electron related to Thermo Electron's guarantee of the Company's outstanding subordinated debentures which are due in 2004, \$5.8 million for capitalized merger transaction costs and \$1.5 million for capital equipment purchases. The capitalized merger transaction costs consisted of banking, legal and accounting costs incurred by Cardiosystems and were capitalized in the purchase consideration (now a component of goodwill).

During the first half of 2001, \$1.3 million of cash was used in financing activities of our Company. Uses of cash included \$1.7 million in common stock repurchases, representing 192,700 shares, which were subsequently retired. On April 12, 2001, we announced a stock repurchase program under which our common stock with a market value up to \$20 million may be acquired in the open market or in privately negotiated transactions. The number of shares to be purchased and the timing of purchases is based on several conditions, including the price of Thoratec stock, general market conditions and other factors. Uses were partially offset by \$415,000 cash received from employee purchases of stock under the Company's stock option plans.

We believe that on-hand cash, short term available-for-sale investments and expected cash flow from operations will be sufficient to fund our operations for at least the next twelve months. We expect that our operating expenses will increase in future periods as we spend more on product manufacturing, marketing and research and development of new product lines as well as substantial costs associated with the assimilation of Cardiosystems with Thoratec and the consolidation of our VAD manufacturing operations.

The impact of inflation on our financial position and results of operations was not significant during the six-month periods ended June 2001 and June 2000.

Results of Operations

Second quarter 2001 and 2000

Product sales in the second quarter of 2001 were \$28.2 million compared to \$22.6 million in the second quarter of 2000, an increase of approximately \$5.6 million or 25%. The increase is primarily attributable to the addition of Thoratec product sales of \$8.5 million during the quarter, partially offset by \$3.0 million lower sales of HeartMate products due to normal fluctuations in the ventricular assist device market and stronger international sales where average selling prices are lower.

Gross margin was \$15.6 million, representing approximately 55% of product sales for the second quarter of 2001 compared to a gross margin of \$13.2 million representing approximately 58% of product sales for the second quarter of 2000. The decrease in gross margin percentage was primarily due to a lower proportion of domestic sales to total product sales. Ventricular assist disposable products, primarily blood pumps that are sold in the United States, generally have higher gross margins than those sold in the rest of the world. Additional contributors to the decrease in gross margin included higher unit production costs due to the manufacturing of fewer HeartMate units than originally planned and employee post-close merger retention costs.

Table of Contents

Research and development expenses were approximately 23% of product sales in the second quarter of 2001 and 17% of product sales in the second quarter of 2000. These expenses increased to \$6.4 million in the second quarter of 2001 from \$3.8 million in the second quarter of 2000, an increase of \$2.6 million, or 69%. The increase was attributable principally to Thoratec's research and development expenses of \$2.0 million for the second quarter of 2001. In addition, product development and clinical study expenses for the HeartMate LVAD products were \$563,000 higher in the second quarter of 2001 compared to the second quarter of 2000.

Selling, general and administrative expenses increased to \$8.3 million in the second quarter of 2001, from \$6.1 million in the second quarter of 2000, an increase of \$2.2 million or 35%. As a percent of sales, these expenses increased from 27% of product sales in 2000 to 29% of product sales in 2001. The increase is primarily due to the addition of \$4.1 million in Thoratec selling, general and administrative expenses, partially offset by lower employee related expenses resulting from the Company's restructuring activities and reduction of \$182,000 in administrative costs paid to Thermo Electron in the second quarter of 2000.

Merger costs were \$768,000 in the second quarter of 2001 and were principally related to employee severance and pre-merger retention costs, and outside consulting, accounting, and legal expenses related to the merger. Restructuring costs of \$837,000 were incurred in the second quarter of 2001, and represent estimated severance costs related to the consolidation of the VAD manufacturing operations.

Amortization of purchased intangibles and goodwill was \$4.5 million in the second quarter of 2001. All purchased intangibles and goodwill were generated due to the merger between Thoratec and Cardiosystems. Until the Company adopts Statement of Financial Accounting Standard (SFAS) No. 142, Business Combinations, further described in Note 5 to the Condensed Consolidated Financial Statements, these costs will be amortized to expense on a straight-line basis over periods ranging from six to twenty years beginning February 14, 2001.

Interest and other income, net, decreased \$692,000, or 54%, in the second quarter of 2001 from the second quarter of 2000. This decrease is due principally to \$523,000 lower interest income caused by both lower cash balances and reduced interest rates as well as \$156,000 lower research and development contract revenues.

The Company's effective tax benefit rate was 34.1% in the second quarter of 2001 as compared to an effective tax provision rate of 38.5% in the second quarter of 2000. The effective tax benefit rate for 2001 differed from the statutory federal income tax rate primarily due to the nondeductible nature of expenses related to the Company's merger with Cardiosystems, including the amortization of goodwill and other nondeductible merger transaction expenses. For 2000, the effective tax provision rate exceeded the federal statutory income tax rate primarily due to the impact of state income taxes.

Six months ended June 2001 and 2000

Product sales in the first half of 2001 were \$49.7 million compared to \$42.5 million in the first half of 2000, an increase of approximately \$7.2 million or 17%. The increase is primarily attributable to the addition of Thoratec product sales of \$12.0 million, partially offset by \$5.5 million in lower sales of HeartMate products due to significant distractions and uncertainties among the Cardiosystems sales force during the first quarter of the year while the merger was being closed.

Gross margin was \$27.0 million, representing approximately 54% of product sales in the first half of 2001 compared to a gross margin of \$25.0 million, representing approximately 59% of product sales, in the first half of 2000. The decrease in gross margin percentage was due primarily to a lower proportion of domestic sales to total product sales. Ventricular assist disposable products, primarily blood pumps that are sold in the United States, generally have a higher gross margin than those sold in the rest of the world. In addition, production costs for the HeartMate product line were higher in the first half of 2001 due to increased inventory reserves for inventory expected to be used in clinical and research and development activities, employee post-close merger retention costs, the manufacturing of fewer HeartMate units than originally planned and higher scrap levels.

Research and development expenses were approximately 23% of product sales in the first half of 2001 and 19% of product sales in the first half of 2000. These expenses increased to \$11.7 million in the first half of 2001 from \$7.9 million in the first half of 2000, an increase of \$3.7 million, or 47%. The increase was attributable principally to Thoratec's research and development expenses of \$3.3 million for the first half of 2001. In addition, product development and clinical study expenses for the HeartMate LVAD products were \$593,000 higher in the first half of 2001 compared to the first half of 2000.

Selling, general and administrative expenses increased to \$15.6 million in the first half of 2001, from \$12.0 million in the first half of 2000, an increase of \$3.6 million or 30%. As a percent of sales, these expenses increased from 28% of product sales in 2000 to 31% of product sales in 2001. The increase is primarily related to the addition of Thoratec's selling, general and administrative expenses, which amounted to \$5.9 million, partially offset by lower overall employee related expenses caused by the Company's restructuring activities and reduction of \$279,000 in administrative costs paid to Thermo Electron in the first half of 2000.

Table of Contents

Merger costs were \$4.3 million in the first half of 2001 and were principally related to employee severance and pre-merger retention costs, and outside consulting, accounting, and legal expenses related to the merger. Restructuring costs of \$837,000 were incurred in the first half of 2001, and represent estimated severance costs related to the consolidation of the VAD manufacturing operations.

Amortization of purchased intangibles and goodwill was \$6.8 million in the first half of 2001. All purchased intangibles and goodwill were generated due to the merger between Thoratec and Cardiosystems. Until the Company adopts Statement of Financial Accounting Standard (SFAS) No. 142, Business Combinations, further described in Note 5 to the Condensed Consolidated Financial Statements, these costs will be amortized to expense on a straight-line basis over periods ranging from six to twenty years beginning February 14, 2001.

In-process research and development expense was \$76.9 million in the first half of 2001, representing a one-time charge related to acquired in-process research and development that had not yet reached technological feasibility and had no alternative future uses. The value assigned to acquired in-process research and development was determined by an independent appraiser, who identified research projects in areas for which technological feasibility had not been established.

Interest and other income, net, decreased \$759,000, or 30%, in the first half of 2001 from the first half of 2000. This decrease is due principally to \$552,000 lower interest income caused by both lower cash balances and reduced interest rates as well as \$263,000 lower research and development contract revenues.

The Company's effective tax benefit rate was 2.4% in the first half of 2001 as compared to an effective tax provision rate of 38.5% in the first half of 2000. The effective tax benefit rate for 2001 differed from the statutory federal income tax rate primarily due to the nondeductible nature of expenses related to the Company's merger with Cardiosystems, including the write off of in-process research and development costs, the amortization of goodwill and other nondeductible merger transaction expenses. For 2000, the effective tax provision rate exceeded the federal statutory income tax rate primarily due to the impact of state income taxes.

Forward-Looking Statements

The statements in this report that relate to future plans, events or performance are forward-looking statements which involve risks and uncertainties. These risks include the results of clinical trials, government regulatory approval processes, delays in product development and new product introductions, announcements by our competitors, an intensely competitive market, the ability to integrate acquired operations and market acceptance of new products.

These factors, and others, are discussed more fully in our annual report on Form 10-K for 2000 and our other filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. These forward-looking statements speak only as of the date hereof.

We undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be needed to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE OF MARKET RISK

We do not currently use derivative financial instruments in our operations or investment portfolio. We do not have material exposure to market risk associated with changes in interest rates. Our subordinated debentures carry a fixed rate of interest and are currently callable at par value. Our investment portfolio at the end of the second quarter 2001 consisted of short-term state and municipal government bonds and money market funds that are classified as available-for-sale and have maturities of less than 90 days. We do not expect to be subject to material interest rate risk with respect to our short-term investments. We do not believe we have any other material exposure to market risk associated with interest rates.

We conduct business in foreign countries. Our international operations consist primarily of sales and service personnel for our ventricular assist products. These employees report into our U.S. sales and marketing group and are internally reported as part of that group. All assets and liabilities of our non-United States operations are translated into United States dollars at the fiscal period-end exchange rates, and, except as follows, the resulting translation adjustments are included in comprehensive income. Exchange rate fluctuations resulting from the period-end translation of the current portion of the intercompany obligation of our wholly owned subsidiary in the United Kingdom into United States dollars are recorded in the income statement as foreign currency exchange gains or losses and are included in interest and other income, net. Net foreign currency exchange loss was approximately \$41,000 and \$102,000, respectively, in the second quarter and first half of 2001. There were no such gains or losses in the second quarter and first

Table of Contents

half of 2000 as the United Kingdom subsidiary became a part of our operations upon the completion of the merger between Thoratec and Cardiosystems on February 14, 2001.

Currently, we do not expect to be subject to material foreign currency risk with respect to future costs or cash flows from our foreign operations and, to date, we have not entered into any significant foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange.

Table of Contents

PART II. OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES

On April 12, 2001 the Company announced that its board of directors authorized a stock repurchase program under which the Company's common stock with a market value up to \$20 million may be acquired in the open market or in privately negotiated transactions. The number of shares to be purchased and the timing of purchases will be based on several conditions, including the price of Thoratec stock, general market conditions and other factors. During the second quarter of 2001, the Company paid approximately \$1.7 million to repurchase 192,700 shares of its common stock, which were retired.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

None

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THORATEC CORPORATION

Date: January 23, 2002

/s/ D. Keith Grossman

D. Keith Grossman,
Chief Executive Officer

Date: January 23, 2002

/s/ M. Wayne Boylston

M. Wayne Boylston,
Senior Vice President,
Chief Financial Officer and Secretary
(Principal Financial and Accounting Officer)